Over the next ten years, PBMs and specialty pharmacies will save payers and patients an estimated total of $250 billion on the cost of specialty medications and related non-drug medical costs when compared to what expenditures would be with limited use of PBMs and specialty pharmacies.
Learn MoreDrug Coupons & Assistance Programs
Fraud, Waste & Abuse
Value & Outcome-Based Contracting
Drug Coverage Mandates
Pharmacy Contracting & Reimbursement
Drug Abuse Prevention
PCMA hosts three annual events: the sPCMA Business Forum, the PBM Policy Forum, and the PCMA Annual Meeting
PCMA’s conference brand is known for bringing together thought leaders and pharmacy benefit decision makers from PBMs, specialty pharmacies, and pharma and biotech manufacturers.
Learn MorePCMA Response to WSJ Op-Ed: “Insurers are Still Denying Treatments for Pre-Existing Conditions”
August 24, 2017
“Insurers are Still Denying Treatments for Pre-Existing Conditions” perfectly reflects the drug lobby’s criticism of the clinical safeguards used to...
PCMA Applauds the Administration’s Effort to Combat the Opioid Crisis
August 08, 2017
(Washington, D.C.) — As the Administration puts forward new steps to curb the rising opioid epidemic, the Pharmaceutical Care Management...
PCMA Response to Wall Street Journal PBM Article
August 07, 2017
In its attempt to find the reason for the high cost of Epipens, “Behind the Push to Keep Higher Priced...
PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others. PBMs are projected to save employers, unions, government programs, and consumers $654 billion— up to 30 percent—on drug benefit costs over the next decade.